Combinations of paclitaxel and etoposide in the treatment of lung cancer

E. A. Perez, C. A. Buckwalter, J. P. Reid

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and etoposide are two chemotherapy agents with broad cytotoxic activity but different mechanisms of action and resistance. Previous in vitro studies of their combined cytotoxicity have yielded conflicting results. We evaluated the effects of drug scheduling in cell growth inhibition in lung and breast human cancer cell lines. A clonogenic assay with either simultaneous or sequential 24-hour incubation of paclitaxel and etoposide was used to assess growth inhibition, and the combination index was used to evaluate drug interactions. In these studies, including the A549 human lung cancer cell line, mild antagonism (combination index, >1) was observed with concurrent exposure of paclitaxel and etoposide, but synergism (combination index, <1) was observed when the drugs were incubated sequentially. In view of the wide range of antitumor activity of both paclitaxel and etoposide, and the potential importance and clinical impact of optimizing drug doses and schedules, we recently completed a phase I study with the following objectives: (1) to determine the maximum tolerated dose of paclitaxel given intravenously on day 10 after 10 days of oral etoposide and (2) to investigate the toxicity profile of this combination of agents. Three consecutive cohorts consisting of a total of 29 patients with various measurable or assessable tumors were treated with paclitaxel by intravenous infusion over 3 hours after receiving 10 days of etoposide 50 mg orally twice daily. Conclusions for this clinical study were that the combination was feasible and tolerable and had demonstrated antitumor activity in a group of mostly pretreated patients. The recommended doses for phase II studies were etoposide 50 mg twice daily for 10 days followed by paclitaxel 150 mg/m2 intravenously over 3 hours. A phase II study in patients with extensive small cell lung cancer, with appropriate translational studies, has been initiated.

Original languageEnglish (US)
Pages (from-to)21-25
Number of pages5
JournalSeminars in Oncology
Volume23
Issue number6 SUPPL. 15
StatePublished - 1996

Fingerprint

Etoposide
Paclitaxel
Lung Neoplasms
Therapeutics
Pharmaceutical Preparations
Cell Line
Maximum Tolerated Dose
Small Cell Lung Carcinoma
Growth
Drug Interactions
Intravenous Infusions
Appointments and Schedules
Breast Neoplasms
Drug Therapy
Lung

ASJC Scopus subject areas

  • Oncology

Cite this

Perez, E. A., Buckwalter, C. A., & Reid, J. P. (1996). Combinations of paclitaxel and etoposide in the treatment of lung cancer. Seminars in Oncology, 23(6 SUPPL. 15), 21-25.

Combinations of paclitaxel and etoposide in the treatment of lung cancer. / Perez, E. A.; Buckwalter, C. A.; Reid, J. P.

In: Seminars in Oncology, Vol. 23, No. 6 SUPPL. 15, 1996, p. 21-25.

Research output: Contribution to journalArticle

Perez, EA, Buckwalter, CA & Reid, JP 1996, 'Combinations of paclitaxel and etoposide in the treatment of lung cancer', Seminars in Oncology, vol. 23, no. 6 SUPPL. 15, pp. 21-25.
Perez EA, Buckwalter CA, Reid JP. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Seminars in Oncology. 1996;23(6 SUPPL. 15):21-25.
Perez, E. A. ; Buckwalter, C. A. ; Reid, J. P. / Combinations of paclitaxel and etoposide in the treatment of lung cancer. In: Seminars in Oncology. 1996 ; Vol. 23, No. 6 SUPPL. 15. pp. 21-25.
@article{eb43de6e0e41417f927b65433636c757,
title = "Combinations of paclitaxel and etoposide in the treatment of lung cancer",
abstract = "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and etoposide are two chemotherapy agents with broad cytotoxic activity but different mechanisms of action and resistance. Previous in vitro studies of their combined cytotoxicity have yielded conflicting results. We evaluated the effects of drug scheduling in cell growth inhibition in lung and breast human cancer cell lines. A clonogenic assay with either simultaneous or sequential 24-hour incubation of paclitaxel and etoposide was used to assess growth inhibition, and the combination index was used to evaluate drug interactions. In these studies, including the A549 human lung cancer cell line, mild antagonism (combination index, >1) was observed with concurrent exposure of paclitaxel and etoposide, but synergism (combination index, <1) was observed when the drugs were incubated sequentially. In view of the wide range of antitumor activity of both paclitaxel and etoposide, and the potential importance and clinical impact of optimizing drug doses and schedules, we recently completed a phase I study with the following objectives: (1) to determine the maximum tolerated dose of paclitaxel given intravenously on day 10 after 10 days of oral etoposide and (2) to investigate the toxicity profile of this combination of agents. Three consecutive cohorts consisting of a total of 29 patients with various measurable or assessable tumors were treated with paclitaxel by intravenous infusion over 3 hours after receiving 10 days of etoposide 50 mg orally twice daily. Conclusions for this clinical study were that the combination was feasible and tolerable and had demonstrated antitumor activity in a group of mostly pretreated patients. The recommended doses for phase II studies were etoposide 50 mg twice daily for 10 days followed by paclitaxel 150 mg/m2 intravenously over 3 hours. A phase II study in patients with extensive small cell lung cancer, with appropriate translational studies, has been initiated.",
author = "Perez, {E. A.} and Buckwalter, {C. A.} and Reid, {J. P.}",
year = "1996",
language = "English (US)",
volume = "23",
pages = "21--25",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 15",

}

TY - JOUR

T1 - Combinations of paclitaxel and etoposide in the treatment of lung cancer

AU - Perez, E. A.

AU - Buckwalter, C. A.

AU - Reid, J. P.

PY - 1996

Y1 - 1996

N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and etoposide are two chemotherapy agents with broad cytotoxic activity but different mechanisms of action and resistance. Previous in vitro studies of their combined cytotoxicity have yielded conflicting results. We evaluated the effects of drug scheduling in cell growth inhibition in lung and breast human cancer cell lines. A clonogenic assay with either simultaneous or sequential 24-hour incubation of paclitaxel and etoposide was used to assess growth inhibition, and the combination index was used to evaluate drug interactions. In these studies, including the A549 human lung cancer cell line, mild antagonism (combination index, >1) was observed with concurrent exposure of paclitaxel and etoposide, but synergism (combination index, <1) was observed when the drugs were incubated sequentially. In view of the wide range of antitumor activity of both paclitaxel and etoposide, and the potential importance and clinical impact of optimizing drug doses and schedules, we recently completed a phase I study with the following objectives: (1) to determine the maximum tolerated dose of paclitaxel given intravenously on day 10 after 10 days of oral etoposide and (2) to investigate the toxicity profile of this combination of agents. Three consecutive cohorts consisting of a total of 29 patients with various measurable or assessable tumors were treated with paclitaxel by intravenous infusion over 3 hours after receiving 10 days of etoposide 50 mg orally twice daily. Conclusions for this clinical study were that the combination was feasible and tolerable and had demonstrated antitumor activity in a group of mostly pretreated patients. The recommended doses for phase II studies were etoposide 50 mg twice daily for 10 days followed by paclitaxel 150 mg/m2 intravenously over 3 hours. A phase II study in patients with extensive small cell lung cancer, with appropriate translational studies, has been initiated.

AB - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and etoposide are two chemotherapy agents with broad cytotoxic activity but different mechanisms of action and resistance. Previous in vitro studies of their combined cytotoxicity have yielded conflicting results. We evaluated the effects of drug scheduling in cell growth inhibition in lung and breast human cancer cell lines. A clonogenic assay with either simultaneous or sequential 24-hour incubation of paclitaxel and etoposide was used to assess growth inhibition, and the combination index was used to evaluate drug interactions. In these studies, including the A549 human lung cancer cell line, mild antagonism (combination index, >1) was observed with concurrent exposure of paclitaxel and etoposide, but synergism (combination index, <1) was observed when the drugs were incubated sequentially. In view of the wide range of antitumor activity of both paclitaxel and etoposide, and the potential importance and clinical impact of optimizing drug doses and schedules, we recently completed a phase I study with the following objectives: (1) to determine the maximum tolerated dose of paclitaxel given intravenously on day 10 after 10 days of oral etoposide and (2) to investigate the toxicity profile of this combination of agents. Three consecutive cohorts consisting of a total of 29 patients with various measurable or assessable tumors were treated with paclitaxel by intravenous infusion over 3 hours after receiving 10 days of etoposide 50 mg orally twice daily. Conclusions for this clinical study were that the combination was feasible and tolerable and had demonstrated antitumor activity in a group of mostly pretreated patients. The recommended doses for phase II studies were etoposide 50 mg twice daily for 10 days followed by paclitaxel 150 mg/m2 intravenously over 3 hours. A phase II study in patients with extensive small cell lung cancer, with appropriate translational studies, has been initiated.

UR - http://www.scopus.com/inward/record.url?scp=0030512947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030512947&partnerID=8YFLogxK

M3 - Article

C2 - 8996593

AN - SCOPUS:0030512947

VL - 23

SP - 21

EP - 25

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 15

ER -